<a href="https://www.fiercebiotech.com/medtech/endoscopic-procedure-can-help-slow-weight-rebound-glp-1-treatment-study" hreflang="en">Endoscopic procedure can help slow weight rebound from stopping GLP-1 treatment: study</a>
A recent study suggests that the endoscopic procedure known as duodenal mucosal resurfacing may help patients maintain weight loss after discontinuing GLP-1 obesity treatments like Eli Lilly's tirzepatide, reducing weight rebound significantly compared to those who did not undergo the procedure. The findings indicate that patients who received the treatment regained less weight and maintained over 80% of their weight loss six months post-cessation of the medication.
Fractyl Health's duodenal mucosal resurfacing, currently used in Europe for type 2 diabetes, shows promise in preventing weight rebound post-GLP-1 treatment, as demonstrated in the REMAIN-1 trial with tirzepatide users. This minimally invasive procedure could represent a significant opportunity for healthtech investors and entrepreneurs to explore, especially considering the potential for U.S. market expansion and the upcoming pivotal data release in Q4, followed by a planned marketing submission.